Company Profile
Inovio Pharmaceuticals Stock Price, News & Analysis
- Ticker:
- INO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.67 USD (-0.47%)
Close
Last updated: August 6, 2026
99.6M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, INO closed down 0.47% at $0.6738. No new same-company headline was identified in the current news window.
Company overview
Business overview
Inovio Pharmaceuticals is a DNA-vaccine and immunotherapy company focused on infectious disease and oncology programs. Its business has long been tied to nucleic-acid delivery and immune activation.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Inovio sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical proof, platform validation, and the ability to turn DNA-based science into durable value.
Position Within the Biotechnology Landscape
Inovio is a high-uncertainty platform biotech whose stock is sensitive to progress and credibility.
Future catalysts
Inovio’s catalysts are INO-3107 and the rest of its DNA-vaccine platform, where the next clinical or regulatory update can either revive or weaken the story. Investors will care about whether the company can keep demonstrating that electroporation-based delivery still matters.
Recent news
- 01
INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Source: Inovio Pharmaceuticals
- 02
Inovio Announces Initiation of “MD Anderson’s HPV-Related Cancers Moon Shot” Phase 2 Trial in New HPV Indications
Source: Inovio Pharmaceuticals
- 03
Inovio, DNA 암호화 단일클론 항체(dMAb™) 플랫폼의 효능 입증하는 임상전 논문 3건과 2019년 첫 임상시험 계획 발표
Source: Inovio Pharmaceuticals
- 04
イノビオ社、3件の前臨床試験で同社のDNAコード化モノクローナル抗体 (dMAb™) プラットフォームの効力をさらに実証し、2019年初旬の初回臨床試験に向けて準備を進める
Source: Inovio Pharmaceuticals
- 05
Inovio在三項臨床前試驗結果文獻中進一步顯示Inovio的DNA編碼單克隆抗體（dMAb™）平台的療效，並準備在2019年初進行首次臨床試驗
Source: Inovio Pharmaceuticals
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inovio Pharmaceuticals (INO)?
Inovio Pharmaceuticals (INO) most recently closed at 0.67 USD, a -0.47% move versus the previous session.
What is the market cap of Inovio Pharmaceuticals (INO)?
Inovio Pharmaceuticals currently has a market capitalization of 99.6M USD on BioPharmSignal.
What does Inovio Pharmaceuticals do?
Inovio Pharmaceuticals is a DNA-vaccine and immunotherapy company focused on infectious disease and oncology programs. Its business has long been tied to nucleic-acid delivery and immune activation.
On which exchange is INO stock listed?
Inovio Pharmaceuticals (INO) is associated with NASDAQ, United States, Biopharma.
What is INO-3107?
Inovio’s catalysts are INO-3107 and the rest of its DNA-vaccine platform, where the next clinical or regulatory update can either revive or weaken the story.
Which conditions is Inovio Pharmaceuticals targeting with INO-3107?
Inovio Pharmaceuticals is associated with oncology based on its company overview and current catalyst commentary.
How does Inovio Pharmaceuticals describe recent progress with INO-3107?
Inovio’s catalysts are INO-3107 and the rest of its DNA-vaccine platform, where the next clinical or regulatory update can either revive or weaken the story.
What is Inovio?
Inovio Pharmaceuticals is a DNA-vaccine and immunotherapy company focused on infectious disease and oncology programs.